Recurrent Uterine Corpus Sarcoma
12
0
0
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
8.3%
1 terminated out of 12 trials
91.7%
+5.2% vs benchmark
8%
1 trials in Phase 3/4
73%
8 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (12)
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery